Prognostic Value of Thrombocytosis in Renal Cell Carcinoma

Abstract

Platelet count appears to be an independent prognostic factor in renal cell carcinoma. It reflects a cascade of biological events correlated with tumor aggressiveness. This observation opens new perspectives for exploring carcinogenesis mechanisms and tumor progression in renal cell carcinoma.

Preoperative Platelet Count and Survival Prognosis in Resected Pancreatic Ductal Adenocarcinoma

“…Platelets play an important role in angiogenesis and proteolysis of the basal membrane, and both situations are present in the process of tumor growth and metastatic spread [7]. Some studies have found that thrombocytosis is associated with poor survival in renal [8][9][10][11][12][13], gynecologic [14][15][16][17][18][19][20][21], and lung tumors [22,23]. Thrombocytosis has also been evaluated in pancreatic carcinoma, but the number of patients studied is small and the results are conflicting [24][25][26].…”

Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer

“…Association of BRAF mutation in PTC with higher peripheral blood platelet counts Prompted by previous findings that elevated peripheral blood platelet count was associated with some human cancers and their aggressiveness (Hernandez et al 2000, Ikeda et al 2002, Verheul & Pinedo 2003, Shimada et al 2004, Brown et al 2005, Bensalah et al 2006, we analyzed the relationship of the BRAF mutation with platelet count and several other hematological and biochemical parameters. This represented an attempt to see if a higher platelet count played any role in BRAF mutation-associated tumor aggressiveness of PTC.…”

“…In the present report, we investigated the relationship of the T1799A BRAF mutation with clinicopathological characteristics of PTC and peripheral platelet counts which are often associated with aggressiveness of other human cancers (Hernandez et al 2000, Ikeda et al 2002, Verheul & Pinedo 2003, Shimada et al 2004, Brown et al 2005, Bensalah et al 2006 to examine the role of this mutation in PTC in Chinese where this mutation has not been well studied.…”

Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma

“…41,[54][55][56][57] Molecular markers including carbonic anhydrase IX, hypoxia inducible factor, Ki67, p53, phosphatase and tensin homolog (PTEN), regulator of apoptosis Bcl-2, Ecadherins, C-reactive protein (CRP), microRNAs (miR-21 and miR-126) and others have demonstrated potential utility as prognostic markers, and vascular endothelial growth factor (VEGF) as predictive biomarker. 58 Higher level of PD-L1 expression has been linked with a negative prognostic factor in RCC.…”